Literature DB >> 22416835

Drug dosage individualization based on a random-effects linear model.

Francisco J Diaz1, Myladis R Cogollo, Edoardo Spina, Vincenza Santoro, Diego M Rendon, Jose de Leon.   

Abstract

This article investigates drug dosage individualization when the patient population can be described with a random-effects linear model of a continuous pharmacokinetic or pharmacodynamic response. Specifically, we show through both decision-theoretic arguments and simulations that a published clinical algorithm may produce better individualized dosages than some traditional methods of therapeutic drug monitoring. Since empirical evidence suggests that the linear model may adequately describe drugs and patient populations, and linear models are easier to handle than the nonlinear models traditionally used in population pharmacokinetics, our results highlight the potential applicability of linear mixed models to dosage computations and personalized medicine.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22416835     DOI: 10.1080/10543406.2010.547264

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  9 in total

1.  Random-effects linear modeling and sample size tables for two special crossover designs of average bioequivalence studies: the four-period, two-sequence, two-formulation and six-period, three-sequence, three-formulation designs.

Authors:  Francisco J Diaz; Michel J Berg; Ron Krebill; Timothy Welty; Barry E Gidal; Rita Alloway; Michael Privitera
Journal:  Clin Pharmacokinet       Date:  2013-12       Impact factor: 6.447

2.  Can valproic acid be an inducer of clozapine metabolism?

Authors:  F J Diaz; C B Eap; N Ansermot; S Crettol; E Spina; J de Leon
Journal:  Pharmacopsychiatry       Date:  2014-04-24       Impact factor: 5.788

Review 3.  Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies.

Authors:  Jose de Leon; Edoardo Spina; Francisco J Diaz
Journal:  Ther Drug Monit       Date:  2013-02       Impact factor: 3.681

4.  Measuring the individual benefit of a medical or behavioral treatment using generalized linear mixed-effects models.

Authors:  Francisco J Diaz
Journal:  Stat Med       Date:  2016-06-20       Impact factor: 2.373

5.  A graphical approach to assess the goodness-of-fit of random-effects linear models when the goal is to measure individual benefits of medical treatments in severely ill patients.

Authors:  Zhiwen Wang; Francisco J Diaz
Journal:  BMC Med Res Methodol       Date:  2020-07-20       Impact factor: 4.615

6.  The Effect of Body Weight Changes on Total Plasma Clozapine Concentrations Determined by Applying a Statistical Model to the Data From a Double-Blind Trial.

Authors:  Francisco J Diaz; Richard C Josiassen; Jose de Leon
Journal:  J Clin Psychopharmacol       Date:  2018-10       Impact factor: 3.153

7.  Role of Statistical Random-Effects Linear Models in Personalized Medicine.

Authors:  Francisco J Diaz; Hung-Wen Yeh; Jose de Leon
Journal:  Curr Pharmacogenomics Person Med       Date:  2012-03

8.  Measuring individual benefits of psychiatric treatment using longitudinal binary outcomes: Application to antipsychotic benefits in non-cannabis and cannabis users.

Authors:  Xuan Zhang; Jose de Leon; Benedicto Crespo-Facorro; Francisco J Diaz
Journal:  J Biopharm Stat       Date:  2020-06-08       Impact factor: 1.503

9.  Individualizing the dosage of Methylphenidate in children with attention deficit hyperactivity disorder.

Authors:  Hoda Shirafkan; Javad Mahmoudi-Gharaei; Akbar Fotouhi; Seyyed Ali Mozaffarpur; Mehdi Yaseri; Mostafa Hoseini
Journal:  BMC Med Res Methodol       Date:  2020-03-11       Impact factor: 4.615

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.